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Background: The constituents of stable multiprotein complexes are known to dissociate from the complex to play
independent regulatory roles. The components of translation elongation complex eEF1H (eEF1A, eEF1Bα, eEF1Bβ,
eEF1Bγ) were found overexpressed in different cancers. To gain the knowledge about novel cancer-related
translational mechanisms we intended to reveal whether eEF1H exists as a single unit or independent subunits in
different human cancers.
Methods: The changes in the expression level of every subunit of eEF1H in the human non-small-cell lung cancer
tissues were examined. The localization of eEF1H subunits was assessed by immunohistochemistry methods,
subcellular fractionation and confocal microscopy. The possibility of the interaction between the subunits was
estimated by co-immunoprecipitation.
Results: The level of eEF1Bβ expression was increased more than two-fold in 36%, eEF1Bγ in 28%, eEF1A in 20%
and eEF1Bα in 8% of tumor specimens. The cancer-induced alterations in the subunits level were found to be
uncoordinated, therefore the increase in the level of at least one subunit of eEF1H was observed in 52% of
samples. Nuclear localization of eEF1Bβ in the cancer rather than distal normal looking tissues was found. In cancer
tissue, eEF1A and eEF1Bα were not found in nuclei while all four subunits of eEF1H demonstrated both cytoplasmic
and nuclear appearance in the lung carcinoma cell line A549. Unexpectedly, in the A549 nuclear fraction eEF1A lost the
ability to interact with the eEF1B complex.
Conclusions: The results suggest independent functioning of some fraction of the eEF1H subunits in human
tumors. The absence of eEF1A and eEF1B interplay in nuclei of A549 cells is a first evidence for non-translational
role of nuclear-localized subunits of eEF1B. We conclude the appearance of the individual eEF1B subunits in
tumors is a more general phenomenon than appreciated before and thus is a novel signal of cancer-related
changes in translation apparatus.
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Living cells present a significant pool of proteins bound
together in stable complexes to perform various bio-
logical functions. Forced dissociation of such complexes
is important for response of the cell to some extracellular
stimuli. Protein synthesis is one of the key milestones in* Correspondence: negrutskii@imbg.org.ua
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includes a great variety of macromolecular complexes.
Deregulation of translational control is a critical feature
of carcinogenesis [1]. The involvement of translation
initiation factors in the cancer progression has been
studied extensively [2-5]. Although the elongation factors
eEF1A and eEF2 are also involved in the abnormal
translation program of cancer cells [6-8], there are very
limited data on whether dissociation of the eEF1H com-
plex is possible during the human cancer progression.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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the eEF1A and eEF1B entities, is involved in the elongation
phase of eukaryotic protein synthesis. eEF1A is responsible
for the delivery of aminoacyl-tRNA to the A site of ribo-
some [9,10]. Eukaryotic eEF1B that consists of the scaffold
(eEF1Bγ) and two catalytic (eEF1Bα and eEF1Bβ) subunits,
catalyzes GDP/GTP exchange in the eEF1A molecule [11].
Apart from their main role in translation, the eEF1H
subunits have been reported to be involved in different pro-
cesses unrelated to the translational apparatus. In particular,
cancer-related overexpression of the eEF1Bβ mRNA was
found in lung cancer [12], medulloblastoma [13] and
oesophageal carcinoma [14]. Up-regulation of the eEF1Bγ
was revealed in breast, colon, gastric and pancreatic tumors
[15-18], whereas the eEF1Bα was overexpressed in breast
cancer [15]. It remains unclear if the cancer-induced
overexpression of the eEF1B subunits is coordinated, or an
increase of each subunit occurs independently.
Previously, we have analyzed the eEF1 subunits expres-
sion at mRNA and protein levels in the samples of human
cardioesophageal and renal carcinomas [19,20]. The un-
balanced expression of eEF1 subunits and the loss of
integrity of the eEF1B complex have been observed in
human cardioesophageal carcinoma rather than in renal
cell carcinoma. That raises the question of whether the
cardioesophageal carcinoma case is unique in relation to
uncoupled changes in the levels of the eEF1B subunits, or
the independent regulation of the subunits expression rep-
resents a more common situation in human cancer tissues.
Here, we performed a systematic analysis of the eEF1
subunits expression in 25 samples of human lung carcin-
oma. Uncoordinated elevation of the eEF1A, eEF1Bβ,
eEF1Bγ and, to some extent, eEF1Bα subunits amount
was found. An increase in the amount of at least one
subunit of the eEF1 complex was found in 52% of the
carcinoma specimens. The loss of the eEF1B integrity was
confirmed by immunohistochemical analysis which dem-
onstrated specific “cyto-nucleo” distribution of eEF1Bβ in
cancer tissue. We have also shown the presence of all
eEF1H subunits and the absence of eEF1A-eEF1B inter-
action in the nuclei of lung adenocarcinoma A549 cells.
Methods
Sample tissues
Twenty-five primary tumor specimens and corresponding
adjacent normal appearing tissue were obtained from 24
patients with NSCLC (19 adenocarcinomas and 5 squa-
mous lung cell carcinomas) and 1 patient with SCLC dur-
ing surgery at the Shupyk National Medical Academy of
Postgraduate Education (Kiev, Ukraine). The ethical
committee of the Institute of Molecular Biology and
Genetics NASU (Kiev, Ukraine) has approved the pro-
ject. All patients who participated in the study signed
informed consent forms.The tissue specimens were immediately immersed in
liquid nitrogen and stored under the same conditions. The
specimens of tumor and correspondingly paired distal
normal appearing tissues were used for mRNA and
protein isolation. For immunohistochemistry analysis, the
tissue samples were fixed in 10% buffered formalin for 48 h.
Plasmids and antibodies
The plasmids with eEF1A1, eEF1A2, eEF1Bα, eEF1Bβ
and eEF1Bγ cDNAs inserts were kindly provided by C.R.
Knudsen, Aarhus University, Denmark, G.M. Janssen,
Leiden University, the Netherlands, V.F. Shalak, Institute
of Molecular Biology and Genetics NASU, Kiev, Ukraine.
The following primary antibodies have been used in ex-
periments: mouse anti-eEF1A (Millipore, USA); in-house
mouse anti-eEF1Bα, anti-eEF1Bβ and rabbit anti-eEF1Bγ
[20]; mouse anti-eEF1Bα, anti-eEF1Bβ and mouse anti-
eEF1Bγ (Abnova, Taiwan); mouse anti-β-actin, (Santa Cruz
Biotechnology, USA), rabbit anti-PARP (Cell Signaling,
USA), rabbit anti-histone H3.3 and mouse anti-β-Tubulin
(Millipore, USA). Immunoblot signals were obtained after
incubation with secondary antibodies conjugated with
horseradish peroxidase using Immobilon Western Chemi-
luminescent HRP Substrate (Millipore, USA). Immuno-
fluoresent detection was done with TRITIC – conjugated
anti-mouse IgG secondary antibodies (Millipore, USA).
Northern blot analysis
Total RNA was isolated from frozen tissues using TRI
Reagent (Sigma, St Louis, MO, USA). The RNA (10 μg per
lane) was electrophoretically separated in 1% agarose gel
containing 2.2 M formaldehyde and then transferred to the
Nytran Nylon N membrane (Whatman, Maidstone, Kent,
UK). Northern blot has been performed as described
earlier [19]. To determine whether the eEF1 mRNAs could
be up- or down-regulated during carcinogenesis, the β-
actin mRNA was used as a reference. No marked tendency
of the overall increase or decrease in the actin mRNA level
in the lung carcinoma samples was revealed when com-
pared to normal samples.
Western blot analysis
The frozen tissue specimens were homogenized in the
presence of liquid nitrogen in a lysis buffer (10 mM
K2HPO4, 100 mM NaCl, 1% NP-40, 1 mM DTT, 0.1 mM
PMSF, pH 7.4), incubated in an ice bath for 30 min and
centrifuged at 13000 g for 20 min at 4°C. The protein
concentration in the supernatants was determined by the
Bradford method [21]. Immunoblotting has been done as
described previously [19]. Endogenous β-actin was used as
a loading control. The densitometry analysis of signals was
performed by the Scion Image program. The target pro-
tein expression was evaluated using the relative intensity
ratio of target protein/loading control.
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tein amount in the tumor samples when compared to
the normal ones were taken as a meaningful difference.
Cell fractionation
A549 cells were cultured in DMEM (Sigma, USA)
growth medium with 10% FBS (Sigma, USA) and 1%
penicillin/streptomycin (Sigma). Cells were grown up to
7×106 cells/ml and harvested with Trypsin-EDTA. Nu-
clear fraction was obtained as described in [22] with
modifications. Cells were resuspended in 1,5 volume of
lysis buffer (10 mM HEPES pH7.9, 1.5 mM MgCl2, 0.5%
NP-40, 0.2 mM PMSF, 0.5 mM DTT) and incubated on
ice for 20 min. Suspended cells were centrifuged at
400 g for 10 min following with supernatant centrifuga-
tion at 16000 g for 30 min. Obtained fraction was used
as cytoplasmic extract. Pellet after low speed centrifuga-
tion was resuspended in 4,5 volumes of sucrose buffer
(10 mM HEPES, 0.25 mM sucrose, 1.5 mM MgCl2,
10 mM KCl, 0.1% NP-40, 0.5 mM DTT, 0.2 mM PMSF)
and incubated on ice for 10 min. Suspension was loaded
on sucrose cushion (2 M sucrose) and centrifuged at
400 g for 10 min. After upper buffer and bottom sucrose
were discarded, nuclei were resuspended in lysis buffer
and centrifuged at 1500 g for 10 min. Procedure was
repeated twice. Nuclear pellet was resuspended in 1/2 of
starting cell volume of nuclear lysis buffer (20 mM
HEPES pH 7.9, 25% glycerol, 0.42 M NaCl, 1.5 mM
MgCl2, 0.2 mM DTT, 0.2 mM EDTA, 0.2 mM PMSF),
incubated on ice for 30 min and centrifuged at 16000 g
for 30 min. Obtained fraction was used as source of
nuclear protein.Figure 1 Comparison of the level of mRNAs coding for different subu
Representative Northern blots are shown. N – normal issue, T – tumor tissu
eEF1Bβ mRNA ~1300 bp, eEF1Bγ mRNA ~1500 bp, β-actin mRNA ~1800 bpThe quality of cytoplasmic and nuclear fractions was
analyzed by Western blot with primary rabbit anti-PARP,
rabbit anti-Histone 3.3 (nuclear markers) and mouse
anti-Tubulin (cytoplasmic marker) antibodies.Immunoprecipitation
Cytoplasmic and nuclear extracts from A549 cells were in-
cubated with Protein G Sepharose (Sigma, USA) for 1 hour
at 4°C. Rabbit anti-eEF1Bγ antibodies (1.5 μg of antibodies
per 1 mg of total protein) were added to pre-cleared lysates
and the incubation persisted for 2 hours at 4°C. To precipi-
tate the antibody-protein complex, Protein G Sepharose
was added according to the manufacturer’s protocol and
incubated for 1 hour at 4°C. To control non-specific bind-
ing with Protein G Sepharose, pre-cleared lysate was in-
cubated with the beads only during 1 hour at 4°C. All
incubations have been done with orbital shaker. The
samples were analyzed by Western blot.Immunohistochemistry and immunofluorescence analysis
Cultured A549 cells were fixed with methanol for 5 min at
room temperature. Thereafter, the cells were permeabilized
with 0.2% Triton X 100 in PBS for 15 min. Non-specific
binding was blocked after incubation with Ultra Vision
Protein Block buffer (Thermo Scientific, USA) for 5 min.
Anti-eEF1Bγ antibodies were applied at dilution 1:100 in
PBS with 1% BSA for 1 hour at 37°C. The secondary
TRITC conjugated anti-mouse antibodies were applied in
dilution 1:100 (Millipore, USA). Cell nuclei were counter-
stained with Hoechst 33258. Samples were washed and em-
bedded into Mowiol medium (Sigma). Microscopy studynits of eEF1H in human lung carcinoma and normal lung.
e. Molecular size: eEF1A1 mRNA ~3500 bp, eEF1Bα mRNA ~850 bp,
. Numeration of samples is according to Table 1.
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scanner microscope (Carl Zeiss, Jena, Germany).
Immunostaining of tissue sections was performed as
described earlier [19].Results
Expression of the mRNAs coding for eEF1H subunits in
the human lung carcinoma tissue
The expression of mRNAs coding for eEF1A1, eEF1Bα,
eEF1Bβ and eEF1Bγ in human lung cancer was assessed
by Northern blot analysis of 25 clinical tumor specimens.
A representative experiment is shown in Figure 1. Analysis
of the expression of mRNA coding for the individual
eEF1H subunits has shown overexpression of eEF1Bβ
mRNA (32% of cases) and eEF1Bγ mRNA (24% of cases)
in cancerous samples (Table 1). The expression of mRNA
coding for the putative oncogenic isoform eEF1A2 was




1 I SCLC 0.5 0.7
2 II Adenocarcinoma 0.8 1.6
3 III Squamous lung cell carcinoma 1.5 1
4 III Adenocarcinoma 0.8 1.7
5 I Adenocarcinoma 1 3.2
6 II Adenocarcinoma 1.7 1.7
7 II Squamous lung cell carcinoma 0.6 0.9
8 II Adenocarcinoma 0.5 1.4
9 II Adenocarcinoma 1 1.5
10 II Adenocarcinoma 0.9 2
11 II Adenocarcinoma 0.7 1.2
12 II Adenocarcinoma 0.7 1.4
13 II Adenocarcinoma 1 2.3
14 I Adenocarcinoma 1.7 1.1
15 II Squamous lung cell carcinoma 0.6 1.6
16 II Adenocarcinoma 1.2 0.9
17 II Squamous lung cell carcinoma 10.6 1.6
18 II Adenocarcinoma 1 2
19 II Adenocarcinoma 0.9 1.8
20 III Adenocarcinoma 3.3 0.7
21 II Adenocarcinoma 0.6 2.1
22 III Adenocarcinoma 0.8 0.6
23 III Squamous lung cell carcinoma 0.7 1.4
24 II Adenocarcinoma 0.6 0.7
25 I Adenocarcinoma 1.1 0.8Expression of protein entities of the eEF1 complex in the
human lung carcinoma tissue
The protein content of eEF1 subunits was examined in the
same tumor samples by Western blot analysis. A representa-
tive experiment is shown in Figure 2. Independent≥ 2-fold
overexpression of at least one eEF1 component was detected
in 52% of all tumor specimens (Table 1). A substantial
cancer-related elevation was observed for the eEF1Bβ (36%)
and eEF1Bγ (28%) subunits. We did not observe any signifi-
cant changes in the eEF1Bα protein level. In fact, eEF1Bα
increased ≥ 2-fold only in two clinical samples out of 25.
Importantly, the unbalanced changes in the eEF1H sub-
units content were observed in the vast majority of the
tumor samples (Table 1). No cancer-induced changes in
the expression level of any subunit were found in three
patients (the patients’ numbers 4, 7, 16). ≥2-fold over-
expression of all eEF1H subunits at protein level in
concert was found only in one case (specimen number 5).
The coordinated increase in the protein amount ofs and corresponding proteins in human lung tumours
Fold expression, tumor/normal tissues
eEF1Bα eEF1Bβ eEF1Bγ
mRNA Protein mRNA Protein mRNA Protein
0.2 0.9 6.4 1 0.4 1.2
0.7 1.3 0.9 1 4.8 2
0.6 1 0.4 1.2 0.2 0.8
0.6 1.2 0.9 1 1.2 1.9
0.9 2.6 1.2 2.6 0.3 2.8
1.3 0.9 0.5 4 1.5 2.3
0.6 1 1.8 1.2 0.8 0.9
1.3 1 0.7 2.5 0.4 0.7
0.8 1 1.6 3 4 0.8
1.6 1.2 1.1 2 5.5 2.6
0.7 1 1.3 0.8 0.5 0.6
0.4 0.7 2.6 0.7 1 0.9
0.7 1.1 1.4 1.8 1.1 1.4
0.9 1.6 8 1.2 1.2 1.8
0.9 0.9 2.2 1.5 0.8 0.3
1.6 1.3 1.1 1.3 1.6 0.9
2.2 3 0.2 1.2 2 0.9
0.9 1.4 1.3 2.4 1.7 1.5
1 1.4 2.2 2 6 2.3
2.9 1.3 4.3 0.6 11 0.6
0.8 1.3 3.2 2.2 1.2 1.3
0.4 1.5 0.2 1.1 1.6 0.5
1.5 1.3 2 2.3 0.8 2.3
0.5 0.9 1.4 0.3 0.7 17
0.2 1.2 0.9 0.5 1 0.7
Figure 2 Comparison of the level of different subunits of eEF1H in human lung carcinoma and normal lung. Representative Western
blots are shown. N – normal tissue, T – tumor tissue. Molecular weights: eEF1A ~50 kDa, eEF1Bα ~28 kDa, eEF1Bβ ~35 kDa, eEF1Bγ ~51 kDa,
β-actin ~42 kDa. Numeration of samples is according to Table 1.
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(patients’ numbers 5, 6, 10, 19, 23), i.e. 71% of the speci-
mens, where the overexpression of eEF1Bγ was found.
The correlation between overexpression of mRNAs coding
for different subunits and the corresponding proteins was
observed in nearly half of the tumor specimens where the
mRNA overexpression was detected.
Nuclear localization of eEF1 components in human lung
Previously, we have observed different locations of the
individual eEF1B subunits in the human cardioesopha-
geal carcinoma samples by immunohistochemical ana-
lysis [19]. To examine whether the eEF1B subunits
demonstrate cancer-related re-localization in human
lung cancer the histochemical analysis was performed
with the lung cancer samples. Strong staining of all tar-
get proteins was detected in both normal and cancer-
ous epithelial cells (Figure 3). Perinuclear appearance
of eEF1A and eEF1Bα was observed in the cells of nor-
mal and cancerous lung tissues. eEF1Bβ was detected
in perinuclear region of normal cells while in the can-
cerous tissue eEF1Bβ showed both cytoplasmic and
nuclear localization. eEF1Bγ was found in cell nuclei
and cytoplasm in the normal and cancerous lung tis-
sues (Figure 3). One may speculate that the simultan-
eous presence of eEF1Bβ and eEF1Bγ in the cancer cell
nuclei may be a tumor-related sign of a suggested
previously binary eEF1Bβ-eEF1Bγ complex, which could
be formed de novo or be a remnant of eEF1H.
To analyze nuclear localization of the eEF1Bβ and
eEF1Bγ subunits in more detail, we isolated the fraction of
nuclear proteins from the human lung adenocarcinomacell line A549. Unexpectedly, all eEF1H subunits were
found to be present in both cytoplasmic and nuclear
fractions of A549 cells (Figure 4A) which contradicted
the data on the cancer tissues where eEF1A and
eEF1Bα were not found in nucleus. The nucleus-
located eEF1A and eEF1Bα did not seem to be contam-
inants from outer side of nuclear membrane, as these
subunits were not present in the nuclear membrane
fraction of A549 cells (Figure 4A). eEF1Bγ was found in
all subcellular fractions including the nuclear membrane
fraction, indicating the possibility of cross-contamination
of the fractions with eEF1Bγ. Therefore, a confocal mi-
croscopy of A549 cells was conducted to specify intra-
cellular localization of eEF1Bγ. As seen in Figure 4B, the
eEF1Bγ subunit was present in both cytoplasm and
nucleus of A549 cells. Thus, in the lung cancer cell line all
subunits of eEF1B demonstrate both cytoplasmic and
nuclear localization.
The question remains whether the nucleus-localized
subunits of eEF1B can interact with each other in A549
cells. Since eEF1Bγ is believed to serve as a core subunit
for the eEF1B complex, we used anti-eEF1Bγ antibodies
to co-precipitate the eEF1Bα and eEF1Bβ subunits from
both cytoplasmic and nuclear fractions of the A549 cell
line (Figure 4C). Co-precipitation of all eEF1B subunits
in the nuclear extract was revealed, suggesting that the
eEF1B complex may be present in the nucleus. Un-
expectedly, in the nuclear fraction of A549 cells the
interaction of the eEF1B complex with eEF1A was not
detected despite eEF1A being present in the nuclear
fraction. Contrary to that, the eEF1A-eEF1B interaction
was observed in the cytoplasmic extract (Figure 4C).
Figure 3 Immunohistochemical analysis of the eEF1H subunits in human lung carcinoma. (A) Normal tissue, (B) Cancerous tissue.
The sample 24 (Table 1) was used for analysis. Magnification is 20x, insert – 100x.
Figure 4 Distribution of the eEF1H subunits in A549 cells. (A) Subcellular fractionation. CE - cytoplasmic extract, NM – nuclear membrane
fraction, NE – nuclear extract, C — control (the pellet after taking out the cytoplasmic fraction and before isolation of nuclei). (B) Immunofluorescent
analysis of eEF1Bγ localization. (a) Localization of eEF1Bγ in A549 cells, (b) nuclear staining with Hoechst 33342, (c) merge. Scale bar 20 μm.
(C) Co-immunoprecipitation of eEF1A and eEF1Bγ. CE – cytoplasmic extract, NE – nuclear extract. IP – fraction of immunoprecipitated proteins,
B – fraction of non-bound proteins.
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Figure 5 Cancer-induced changes in the composition of the eEF1H complex. In cancer cells, both eEF1B and its individual subunits are
present, as well as hypothetic eEF1Bβ-eEF1Bγ complex. eEF1Bβ and eEF1Bγ may contribute to the cancer development while a role of individual
eEF1Bα is unknown.
Table 2 Overexpression of eEF1H subunits at protein










eEF1A 36 20 5
eEF1Bα 20 8 0
eEF1Bβ 36 36 5
eEF1Bγ 36 28 5
All subunits 72 52 16
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The lack of correlated changes in the expression level of
all eEF1H subunits suggests the presence of the individ-
ual, non-complexed subunits of eEF1H in lung cancer
tissue. Oncogenic properties of eEF1Bβ were described
earlier [23]. In particular, overexpression of eEF1Bβ
inhibits E3 ubiquitin ligase SIAH- 1, the enzyme which
can suppress tumor development via targeting of onco-
genic and anti-apoptotic proteins [24,25]. The role of in-
dividual eEF1Bγ in cancer is not so clear. This subunit is
a participant of oxidative stress response pathway. In the
absence of eEF1Bγ this pathway is constitutively active
[26], thus, overexpression of individual eEF1Bγ in tumor
cells may impair cellular ROS detoxification, which sen-
sitizes tumor cells to ROS-induced cell death. Recently,
it has been shown that eEF1Bγ, being phosphorylated at
Ser294 by DOA protein kinase, down-regulates transport
of several classes of membrane organelles, including
peroxisomes and mitochondria, along microtubules [27].
An effect of this phosphorylation on the ability of eEF1Bγ
to be in complex with other subunits of eEF1B remains to
be investigated. Recently, ectopically expressed individual
eEF1Bγ was shown to interact with NFκB and positively
regulate NFκB-mediated signal cascades [28]. NFκB is
known factor of cancer-related inflammation which is
widely involved in the initiation and progression of cancer.
The functions of a protein may depend on whether or
not this protein is present in a cell as a single entity or as a
component of high-molecular weight complex [29]. Our
hypothesis is that the eEF1B complex functions in the
same way both in tumor and in normal tissues, providing
nascent polypeptide elongation process with the GTP-
bound form of eEF1A while free subunits of eEF1B aredirected towards fulfillment of different cancer-related
duties (Figure 5).
It is noteworthy that more than 2-fold elevation of
eEF1Bβ protein in the cancer tissues relative to the
control has occurred in 71% of the specimens which
demonstrate the eEF1Bγ overexpression (Table 2). Simi-
lar coordinated increase of eEF1Bβ and eEF1Bγ subunits
content was observed previously in human cardioesopha-
geal carcinoma [19]. Parallel increase in the eEF1Bβ and
eEF1Bγ amount in cancer tissues hints that these subunits
of eEF1B may act together under cancer conditions.
eEF1Bβ plays a role as a guanine exchange factor, while
eEF1Bγ may serve as an anchoring unit for eEF1Bβ, provid-
ing specific subcellular localization of the latter. Import-
antly, the literature data suggest that both eEF1Bβ and
eEF1Bγ possess pro-tumor properties [30-35] while eEF1Bα
does not (Figure 5).
Subcellular localization of the eEF1H subunits was
investigated in the lung cancer tissue samples and cell
line. All eEF1H subunits were found in nuclei of A549
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nuclear localization was found in the lung cancer speci-
mens by immunohistochemical investigation (Figure 3).
This difference may be patient-specific or represent a
genuine divergence in the eEF1B localization between
cultivating cells and cancer tissues. More importantly, the
immunoprecipitation analysis did not reveal the classic
eEF1H complex in nucleus, as the eEF1A-eEF1B inter-
action was not detected there despite the presence of all
factors in the nuclear fraction. Molecular reasons for this
are under investigation and may be related to a different
level of post-translational modifications of the eEF1A or
eEF1B components. Notably, the phosphorylation of
eEF1Bβ can influence its interaction with eEF1A [36]. A
reason for the presence of the eEF1H subunits in nucleus
is unknown. The data on the existence of nuclear protein
synthesis remain controversial [36-43]. As eEF1A and
eEF1B did not interact in the nuclear fraction of the
cancer cells, this argues against nuclear translation and
suggests independent roles of eEF1A and eEF1B. eEF1B
was reported to participate in the cell cycle events [44],
interact with NFκB [28], play an essential role in the
oxidative stress response pathway [26,45], contribute to cyto-
skeleton rearrangements [46] and proteolytic system [47].
The analysis of data described here and in [19] un-
covered an interesting trend related to overexpression of
the eEF1H subunits in different human cancers (Table 2).
Cardioesophageal and lung carcinomas showed in-
creased level of expression of all eEF1H subunits observed
in 8-36% of all samples, depending on the subunit and
tumour type. However, as the changes in the subunits
expression are not coordinated, the elevated protein levels
of one or another subunit expression were found in 72%
of cardioesophageal [19] and 52% of lung carcinomas.
Interestingly, we did not observe marked difference in the
eEF1H proteins expression in human kidney tumours [20]
where the overexpression of the eEF1A and eEF1Bγ pro-
teins was found in two diverse tumour samples out from
eighteen specimens researched. This finding favours the
specificity of the phenomenon and suggests that the com-
bined increase of different eEF1B subunits of the eEF1H
complex may be considered as useful addition to the panel
of markers for lung and cardioesophageal carcinomas.Conclusions
Taken together, our data revealed that structurally and
functionally independent existence of the subunits of the
translation elongation complex eEF1B in tumour tissues
may be a widespread, albeit specific phenomenon. This
finding provides new insights into understanding of
principles of the organization of translation apparatus in
cancer cells and contributes to the panel of potential
markers for lung and cardioesophageal carcinomas.Abbreviations
eEF1H: “heavy” form of translation elongation factors complex;
eEF1A: subunit A of eEF1H; eEF1B: sub-complex of eEF1H which consists
from eEF1Bα, eEF1Bβ and eEF1Bγ subunits; SCLC: small cell lung carcinoma.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
MV performed experimental research on mRNA, protein expression, cell
fractionation and immunoprecipitation, LK performed experiments on cell
fractionation and immunofluorescence, AK participated in immunohistochemical
analysis, VZ collected and analysed tissue specimens, BN designed the study and
wrote manuscript, AE wrote and edited the manuscript. All authors read and
approved the final manuscript.
Acknowledgements
We thank O. Koroliov for participation in the studies and K. Albert for editing
of the manuscript.
Research was partially supported by funds from France-Ukraine PICS and
GDRI programs.
Author details
1State Key Laboratory of Molecular and Cellular Biology, Institute of
Molecular Biology and Genetics NASU, 150 Acad.Zabolotnogo Str., Kiev
03680, Ukraine. 2Shupyk National Medical Academy of Postgraduate
Education, 9 Dorohozhyts’ka str., Kiev 04112, Ukraine.
Received: 1 July 2014 Accepted: 25 November 2014
Published: 3 December 2014
References
1. Stumpf CR, Ruggero D: The cancerous translation apparatus. Curr Opin
Genet Dev 2011, 21(4):474–483.
2. Robert F, Pelletier J: Translation initiation: a critical signalling node in
cancer. Expert Opin Ther Targets 2009, 13(11):1279–1293.
3. Rosenwald IB, Hutzler MJ, Wang S, Savas L, Fraire AE: Expression of
eukaryotic translation initiation factors 4E and 2alpha is increased
frequently in bronchioloalveolar but not in squamous cell carcinomas of
the lung. Cancer 2001, 92:2164–2171.
4. Brass N, Heckel D, Sahin U, Pfreundschuh M, Sybrecht GW, Meese E:
Translation initiation factor eIF-4gamma is encoded by an amplified
gene and induces an immune response in squamous cell lung
carcinoma. Hum Mol Genet 1997, 6:33–39.
5. Bauer C, Brass N, Diesinger I, Kayser K, Grasser FA, Meese E: Overexpression
of the eukaryotic translation initiation factor 4G (eIF4G-1) in squamous
cell lung carcinoma. Int J Cancer 2002, 98:181–185.
6. Vislovukh A, Kratassiouk G, Porto E, Gralievska N, Beldiman C, Pinna G,
El'skaya A, Harel-Bellan A, Negrutskii B, Groisman I: Proto-oncogenic isoform
A2 of eukaryotic elongation factor eEF1 is a target of miR-663 and
miR-744. Br J Cancer 2013, 108(11):2304–2311.
7. Joseph P, O'Kernick CM, Othumpangat S, Lei YX, Yuan BZ, Ong TM:
Expression profile of eukaryotic translation factors in human cancer
tissues and cell lines. Mol Carcinog 2004, 40(3):171–179.
8. Oji Y, Tatsumi N, Fukuda M, Nakatsuka S, Aoyagi S, Hirata E, Nanchi I, Fujiki
F, Nakajima H, Yamamoto Y, Shibata S, Nakamura M, Hasegawa K, Takagi S,
Fukuda I, Hoshikawa T, Murakami Y, Mori M, Inoue M, Naka T, Tomonaga T,
Shimizu Y, Nakagawa M, Hasegawa J, Nezu R, Inohara H, Izumoto S,
Nonomura N, Yoshimine T, Okumura M, et al.: The translation elongation
factor eEF2 is a novel tumor‑associated antigen overexpressed in various
types of cancers. Int J Oncol 2014, 44(5):1461–1469.
9. Lukash TO, Turkivska HV, Negrutskii BS, El'skaya AV: Chaperone-like activity
of mammalian elongation factor eEF1A: renaturation of aminoacyl-tRNA
synthetases. Int J Biochem Cell Biol 2004, 36(7):1341–1347.
10. Kanibolotsky DS, Novosyl'na OV, Abbott CM, Negrutskii BS, El'skaya AV:
Multiple molecular dynamics simulation of the isoforms of human
translation elongation factor 1A reveals reversible fluctuations between
"open" and "closed" conformations and suggests specific for eEF1A1
affinity for Ca2+−calmodulin. BMC Struct Biol 2008, 8:4.
11. Andersen GR, Nissen P, Nyborg J: Elongation factors in protein
biosynthesis. Trends Biochem Sci 2003, 28(8):434–441.
Veremieva et al. BMC Cancer 2014, 14:913 Page 9 of 9
http://www.biomedcentral.com/1471-2407/14/91312. Liu Y, Chen Q, Zhang JT: Tumor suppressor gene 14-3-3sigma is
down-regulated whereas the proto-oncogene translation elongation
factor 1delta is up-regulated in non-small cell lung cancers as identified
by proteomic profiling. J Proteome Res 2004, 3(4):728–735.
13. De Bortoli M, Castellino RC, Lu XY, Deyo J, Sturla LM, Adesina AM, Perlaky L,
Pomeroy SL, Lau CC, Man TK, Rao PH, Kim JY: Medulloblastoma outcome is
adversely assotiated with overexpression of EEF1D, RPL30, and RPS20 on
the long arm of chromosome 8. BMC Cancer 2006, 6:223.
14. Ogawa K, Utsunomiya T, Mimori K, Tanaka Y, Tanaka F, Inoue H, Murayama
S, Mori M: Clinical significance of elongation factor-1 delta mRNA
expression in oesophageal carcinoma. Br J Cancer 2004, 91:282–286.
15. Al-Maghrebi M, Anim JT, Olalu AA: Up-regulation of eukaryotic elongation
factor-1 subunits in breast carcinoma. Anticancer Res 2005, 25:2573–2577.
16. Chi K, Jones DV, Frazier ML: Expression of an elongation factor 1
gamma-related sequence in adenocarcinomas of the colon.
Gastroenterology 1992, 103:98–102.
17. Mimori K, Mori M, Tanaka S, Akiyoshi T, Sugimachi K: The overexpression of
elongation factor 1 gamma mRNA in gastric carcinoma. Cancer 1995,
75(Suppl. 6):1446–1449.
18. Lew Y, Jones DV, Mars WM, Evans D, Byrd D, Frazier ML: Expression of
elongation factor-1 gamma-related sequence in human pancreatic
cancer. Pancreas 1992, 7:144–152.
19. Veremieva M, Khoruzhenko A, Zaicev S, Negrutskii B, El’skaya A:
Unbalanced expression of the translation complex eEF1 subunits in
human cardioesophageal carcinoma. Eur J Clin Investig 2011, 41:269–276.
20. Veremieva MV, Zgonnik YM, Negrutskii BS, El'skaya AV: Expression of the
subunits of multiprotein translation elongation complex eEF1H in
human renal carcinomas. Biopolym Cell 2011, 27:279–284.
21. Bradford M: A rapid and sensitive method for the quantitation of
microgram quantities of protein utilizing the principle of protein-dye
binding. Anal Biochem 1976, 72:248–254.
22. Dignam JD, Lebovitz RM, Roeder RG: Accurate transcription initiation by
RNA polymerase II in a soluble extract from isolated mammalian nuclei.
Nucleic Acids Res 1983, 11(5):1475–1489.
23. Joseph P, Lei YX, Ong TM: Up-regulation of expression of translation
factors—a novel molecular mechanism for cadmium carcinogenesis.
Mol Cell Biochem 2004, 255(1–2):93–101.
24. Matsuzawa SI, Reed JC: Siah-1, SIP, and Ebi collaborate in a novel
pathway for beta-catenin degradation linked to p53 responses.
Mol Cell 2001, 7(5):915–926.
25. Yoshibayashi H, Okabe H, Satoh S, Hida K, Kawashima K, Hamasu S,
Nomura A, Hasegawa S, Ikai I, Sakai Y: SIAH1 causes growth arrest and
apoptosis in hepatoma cells through beta-catenin degradation-
dependent and –independent mechanisms. Oncol Rep 2007,
17(3):549–556.
26. Esposito AM, Kinzy TG: The eukaryotic translation elongation Factor
1Bgamma has a non-guanine nucleotide exchange factor role in protein
metabolism. J Biol Chem 2010, 285(49):37995–38004.
27. Serpinskaya AS, Tuphile K, Rabinow L, Gelfand VI: Protein kinase Darkener
of apricot and its substrate EF1γ regulate organelle transport along
microtubules. J Cell Sci 2014, 127(Pt 1):33–39.
28. Liu D, Sheng C, Gao S, Jiang W, Li J, Yao C, Chen H, Wu J, Chen S, Huang W:
eEF1Bγ is a positive regulator of NF-кB signaling pathway.
Biochem Biophys Res Commun 2014, 446(2):523–528.
29. Ray PS, Arif A, Fox PL: Macromolecular complexes as depots to releasable
regulatory proteins. Trends Biochem Sci 2007, 32(4):158–164.
30. Joseph P, Lei YX, Whong WZ, Ong TM: Oncogenic potential of mouse
translation elongation factor-1 delta, a novel cadmium-responsive
proto-oncogene. J Biol Chem 2002, 277(8):6131–6136.
31. Old WM, Shabb JB, Houel S, Wang H, Couts KL, Yen CY, Litman ES, Croy CH,
Meyer-Arendt K, Miranda JG, Brown RA, Witze ES, Schweppe RE, Resing KA,
Ahn NG: Functional proteomics identifies targets of phosphorylation by
B-Raf signaling in melanoma. Mol Cell 2009, 34(1):115–131.
32. Lu Q, Lei YX, He CC, Lei ZN: Blood translation elongation factor-1δ is a
novel marker for cadmium exposure. Int J Mol Sci 2013, 14(3):5182–5197.
33. Chen L, Chen W, Zhao L, Yu HZ, Li X: Immunoscreening of urinary bladder
cancer cDNA library and identification of potential tumor antigen.
World J Urol 2009, 27(1):107–112.
34. Liu H, Han Y, Mi R, Zhang Y, Su G, Wang H, Zhou X, Liu X, Zhu B: Identification
of cervical cancer proteins associated with treatment with paclitaxel and
cisplatin in patients. Int J Gynecol Cancer 2011, 21(8):1452–1457.35. Zheng G, Peng F, Ding R, Yu Y, Ouyang Y, Chen Z, Xiao Z, He Z:
Identification of proteins responsible for the multiple drug resistance in
5-fluorouracil-induced breast cancer cell using proteomics analysis.
J Cancer Res Clin Oncol 2010, 136(10):1477–1488.
36. Sivan G, Aviner R, Elroy-Stein O: Mitotic modulation of translation elongation
factor 1 leads to hindered tRNA delivery to ribosomes. J Biol Chem 2011,
286:27927–27935.
37. Nathanson L, Xia T, Deutscher MP: Nuclear protein synthesis: a re-evaluation.
RNA 2003, 9(1):9–13.
38. Belgrader P, Cheng J, Maquat LE: Evidence to implicate translation by
ribosomes in the mechanism by which nonsense codons reduce the
nuclear level of human triosephosphate isomerase mRNA. Proc Natl Acad
Sci U S A 1993, 90(2):482–486.
39. Birnstiel ML, Flamm WG: Intranuclear site of histone synthesis.
Science 1964, 145(3639):1435–1437.
40. Iborra FJ, Jackson DA, Cook PR: Coupled transcription and translation
within nuclei of mammalian cells. Science 2001, 293(5532):1139–1142.
41. Bohnsack MT, Regener K, Schwappach B, Saffrich R, Paraskeva E, Hartmann E,
Görlich D: Exp5 exports eEF1A via tRNA from nuclei and synergizes
with other transport pathways to confine translation to the cytoplasm.
EMBO J 2002, 21(22):6205–6215.
42. Dahlberg JE, Lund E: Does protein synthesis occur in the nucleus?
Curr Opin Cell Biol 2004, 16(3):335–338.
43. David A, Dolan BP, Hickman HD, Knowlton JJ, Clavarino G, Pierre P,
Bennink JR, Yewdell JW: Nuclear translation visualized by ribosome-bound
nascent chain puromycylation. J Cell Biol 2012, 197(1):45–57.
44. Boulben S, Monnier A, Le Breton M, Morales J, Cormier P, Belle R,
Mulner-Lorillon O: Sea urchin elongation factor 1delta (EF1delta) and
evidence for cell cycle-directed localization changes of a sub-fraction
of the protein at M phase. Cell Mol Life Sci 2003, 60:2178–2188.
45. Olarewaju O, Ortiz PA, Chowdhury WQ, Chatterjee I, Kinzy TG:
The translation elongation factor eEF1B plays a role in the oxidative
stress response pathway. RNA Biol 2004, 1:89–94.
46. Kim S, Kellner J, Lee CH, Coulombe PA: Interaction between the keratin
cytoskeleton and eEF1Bgamma affects protein synthesis in epithelial
cells. Nat Struct Mol Biol 2007, 14:982–983.
47. Wu H, Shi Y, Lin Y, Qian W, Yu Y, Huo K: Eukaryotic translation elongation
factor 1 delta inhibits the ubiquitin ligase activity of SIAH-1.
Mol Cell Biochem 2011, 357(1–2):209–215.
doi:10.1186/1471-2407-14-913
Cite this article as: Veremieva et al.: Independent overexpression of the
subunits of translation elongation factor complex eEF1H in human lung
cancer. BMC Cancer 2014 14:913.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
